IOVA IOVANCE BIOTHERAPEUTICS, INC.

company

SEC Filings & Insider Trading Activity 2026

Business Overview

• • Core business: Commercial-stage biopharma pioneering individualized tumor infiltrating lymphocyte (TIL) cell therapies for solid tumor cancers
• • New/regulatory: Amtagvi approved in U.S. and Canada, pending UK/Australia 2026 approvals, withdrawn and resubmitting EU MAA in 2026
• • Strategic shift: Transitioned all Amtagvi/lifileucel manufacturing in-house at FDA-approved iCTC facility, ending contract manufacturing early 2026
• • Quantitative highlight: Over 1,500 patients treated with commercial/investigational TIL therapies; iCTC capacity >5,000 patients annually
• • Noteworthy fact: Presented first real-world Amtagvi data (44% ORR) in 2026; advancing Phase 3 TILVANCE-301 trial combining lifileucel with pembrolizumab in frontline melanoma

Risk Factors

• • Cybersecurity risk from internal systems and CROs, requiring increased resources to counter sophisticated threats
• • Dependency on IT infrastructure vulnerable to security breaches impacting business operations
• • Audit Committee oversight on internal controls risks related to cybersecurity threats
• • Management led by VP, Infrastructure and Security with professional cybersecurity certifications tasked with risk management
• • External cybersecurity consultants employed alongside internal team for enhanced protection measures

Management Discussion & Analysis

• • Revenue $263.5M, up 61% YoY; Amtagvi $220.0M (up $116.5M), Proleukin $43.5M (down $17.0M)
• • Cost of sales $173.2M, up 86%; R&D $300.3M, up 9%; SG&A flat at $152.3M; total expenses $666.9M, up 19%
• • Best performing segment: Amtagvi revenue $220.0M, worst: Proleukin revenue down 28% to $43.5M
• • No explicit cash flow, buybacks, dividends data provided; capex details not disclosed
• • Outlook: expect European MAA resubmission in 2026; ongoing clinical trials in multiple indications; focus on global commercial expansion and manufacturing optimization

What are the latest IOVA SEC filings in 2026?

IOVANCE BIOTHERAPEUTICS, INC. (IOVA) has filed a 10-K annual report on February 24, 2026, a 10-Q quarterly report on May 7, 2026, an 8-K current report on August 6, 2026 with the SEC. SignalX tracks every new SEC EDGAR filing daily, including 10-K, 10-Q, 8-K, and Form 4 insider transactions, with AI-powered summaries of key sections.

When did IOVA file its most recent 10-K annual report?

IOVANCE BIOTHERAPEUTICS, INC. (IOVA) filed its most recent 10-K annual report on February 24, 2026. The 10-K includes audited financial statements, business overview, risk factors, and management discussion, all available on SignalX with AI-generated summaries and XBRL financial data.

How do I view IOVA 10-Q quarterly reports?

IOVANCE BIOTHERAPEUTICS, INC. (IOVA)'s most recent 10-Q quarterly report was filed on May 7, 2026. SignalX displays every IOVA 10-Q with AI-generated summaries of the MD&A (Management Discussion & Analysis) and Risk Factors sections, plus links to the original SEC EDGAR document.

What 8-K current reports has IOVA filed recently?

IOVANCE BIOTHERAPEUTICS, INC. (IOVA)'s most recent 8-K was filed on August 6, 2026. 8-K filings disclose material corporate events such as earnings releases, executive changes, mergers, and other significant developments. SignalX surfaces each 8-K with item-level summaries so you can quickly see what happened.

Where can I find IOVA insider trading activity (Form 4)?

SignalX aggregates every IOVA Form 4 insider transaction from SEC EDGAR. Form 4 reports show when officers, directors, and 10% shareholders buy or sell company stock, with transaction code, share count, and price per share.

How often does IOVA file with the SEC?

IOVANCE BIOTHERAPEUTICS, INC. (IOVA) files a 10-K annual report once per year (typically within 60 days of fiscal year-end) and 10-Q quarterly reports three times per year. 8-K current reports are filed as needed when material events occur, and Form 4 insider transaction reports are due within two business days of a trade. SignalX monitors SEC EDGAR daily to surface every new IOVA filing with AI-powered analysis.

What is the difference between 10-K, 10-Q, and 8-K SEC filings?

A 10-K is a comprehensive annual report with audited financials, business overview, and risk factors. A 10-Q is a shorter quarterly report with unaudited financials and management discussion. An 8-K is a current report filed when a material event occurs, such as earnings releases, executive changes, acquisitions, or other significant developments. SignalX provides AI-generated summaries for all three filing types for IOVANCE BIOTHERAPEUTICS, INC. (IOVA).

What is IOVA's SEC CIK number?

IOVANCE BIOTHERAPEUTICS, INC. (IOVA)'s SEC CIK (Central Index Key) number is 1425205. The CIK is a unique identifier assigned by the SEC to every filing entity. You can use CIK 1425205 to look up all IOVA filings on SEC EDGAR, or browse them here on SignalX with AI-powered analysis.

Where can I find IOVA return on equity (ROE) and financial data?

SignalX extracts XBRL financial data from IOVANCE BIOTHERAPEUTICS, INC. (IOVA) 10-K annual filings, including revenue, net income, gross profit, operating income, EPS, total assets, stockholders' equity, and operating cash flow. Return on equity (ROE) can be derived from net income divided by stockholders' equity. Multi-year financial trends are displayed in the Financial Summary table above.